COVID-19: Current and Future Impacts
-
Register
- Non-Member - $39
- Regular Member - $29
- Retired - $29
- Early Career Physician - $29
- Resident - $19
- Student - $19
- Associate - $19
- ASAM Staff - Free!
- International Member - $29
- Emeritus Member - $29
- Provisional Member - $29
- Fellow Member - $29
- Honorary Member - $29
- CRT Member - $29
COVID-19: Current and Future Impacts
Recorded: Thursday, September 29, 2022 - Saturday, October 1, 2022
On-Demand Session
Overview
This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course reviews the latest research developments on the current an future impacts of COVID-19 and potential solutions.
The COVID-19 era has given rise to a series of major life stressors, including illness and death caused by a global pandemic, stay-at-home orders, disruptions in employment and income, food and supply shortages, as well as housing instability. As a result of these factors, epidemiological evidence suggests that the pandemic has increased alcohol use, opioid use, and the prevalence of certain psychological disorders. Furthermore, minoritized persons with substance use disorders are a particularly vulnerable population because of their unique social and health care needs, which place them at risk for significant harm from both the pandemic itself and its social and economic consequences. This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course explores the impacts of the COVID-19 pandemic as well as potential solutions. Following each presentation, presenters answer audience questions.
This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.
- Emerging Trends in Alcohol Misuse and Related Harms During and After the Pandemic
Epidemiological evidence suggests a mixed picture for alcohol use during the COVID-19 pandemic. Overall, there was a trend towards increased alcohol consumption, with some groups, including women, showing greater increases than others. After increasing around 2.2% per year over the previous two decades, deaths involving alcohol jumped 25.5% between 2019 to 2020. Mental health factors were the most common correlates or triggers for increased use of alcohol. There is a need for increased vigilance for alcohol-related problems and there is likely to be an increase in the need for alcohol treatment. Problematic alcohol use which is not addressed can lead to adverse consequences for individuals and families, and has significant costs for health systems. - Opioid Use Disorder Treatment without Red Tape? What We Learned During COVID-19
Access to medications for opioid use disorder (MOUD), including methadone and buprenorphine, are substantially restricted by controlled substance regulations that present a burden to many patients. For example, methadone patients are typically required to travel to opioid treatment programs daily to receive observed doses of medication and buprenorphine patients have not historically been allowed to start medication based on a telephone or video consult. However, many regulations were suspended or modified after the COVID-19 public health emergency. This "natural experiment" has taught the field important lessons about possible new directions for increasing access, such as take home methadone and telehealth for buprenorphine, in a less burdensome manner. This talk will review the evidence in support of the argument for making the COVID-19 regulations permanent. - Racism, COVID-19, and Racial/Ethnic Behavioral Health Inequities
Racial and ethnic minorities have shouldered a disproportionate medical, emotional and social burden of the COVID-19 pandemic. This presentation will discuss racial and ethnic disparities in COVID-19 infection and associated consequences. The presentation will highlight the contribution of structural racism on disparities in social determinants of health that place Black, Latinx and Other People of Color at increased risk for Covid-19 infection, morbidity and mortality. It will also explore the intersectionality of race and substance use disorder on COVID-related outcomes for minoritized populations, especially Black persons in the United States. - Symptoms of Psychological Distress Among U.S. Adults over the Course of the COVID-19 Pandemic
This presentation will describe a longitudinal survey of a nationally representative cohort of U.S. adults measuring psychological distress in April 2020, July 2020, November 2020, and July 2021. Study results include measures of psychological distress, using the validated Kessler-6 measure, at each time point, as well as measures of treatment seeking and receipt. Discussion will focus on the trajectory of psychological distress over the course of the COVID-19 pandemic among U.S. adults overall and among specific demographic sub-groups. The presentation will conclude with consideration of the implications of study results for public mental health moving forward.
These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:
- Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
- Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
- Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine
This conference addresses all 6 ACGME Competencies.
Learning Objectives
At the end of the course, learners should be able to:
- Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
- Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
- Develop practical applications for integrating new and emerging science into practice.
- Identify gaps in the field of addiction medicine that future research can address.
- Create a network of colleagues and resources to support the learner's practice or form future research collaborations.
Registration Rates
ASAM Learner Type | Rate |
ASAM Member | $29 |
Non-Member | $39 |
Associate Member | $19 |
Resident Member* | $19 |
Student Member* | $19 |
*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.
Membership Question? Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.
Refunds & Cancellations
All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.
Registration Deadline: 10/1/2025
Instructions
- Click on the Contents tab to begin this activity.
- Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
- Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
- Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.
Need Assistance?
For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org
ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.
Michael Fingerhood, MD, FACP, DFASAM (Moderator)
Associate Professor of Medicine and Public Health
Johns Hopkins University
Dr. Michael Fingerhood is an Associate Professor of Medicine and Public Health at the Johns Hopkins University. He is the Chief of the Division of Chemical Dependence and medical director of the Comprehensive Care Practice (CCP) at Johns Hopkins Bayview Medical Center. The CCP integrates substance use disorder treatment with primary medical care, including care for HIV and hepatitis C.
No Relevant Financial Disclosures
Aaron White, PhD
Leader, Epidemiology and Biometry Branch and Senior Scientific Advisor to the Director
National Institute on Alcohol Abuse and Alcoholism
Aaron White is the Senior Scientific Advisor to the Director at the National Institute on Alcohol Abuse and Alcoholism (NIAAA). His areas of scientific expertise include the brain mechanisms and epidemiology of alcohol-induced memory blackouts, and the impact of alcohol and other drugs on brain function and behavior, particularly during the adolescent years.
Dr. White co-wrote the online alcohol prevention course, AlcoholEdu, which has been completed by more than 3 million high school and college students to date. He joined NIAAA in 2008 and, until recently, was a Program Officer in the Division of Epidemiology and Prevention Research. As a Program Officer, Dr. White oversaw a large portfolio of grants covering epidemiology and prevention research related to underage and college drinking. In 2015, he was promoted to Senior Scientific Advisor to the Director, Dr. George Koob. In this position, Dr. White advises the Director regarding a wide variety of scientific topic areas in alcohol and other drug research.
He also frequently takes part in media interviews and delivers presentations on behalf of the Institute, including presentations on addiction and overdoses at a meeting of the United Nations Office of Drugs and Crime in Austria last fall. He is an author on 37 peer-reviewed manuscripts, 22 review papers and book chapters, 3 books and has delivered several hundred presentations about alcohol and the brain.
No Relevant Financial Disclosures
Brendan Saloner, PhD
Associate Professor
Johns Hopkins Bloomberg School of Public Health
Brendan Saloner, PhD, is a Bloomberg Associate Professor of Addiction and Overdose in the Department of Health Policy and Management. One strand of his research focuses on access and quality of care for people with mental health and substance use disorders. Professor Saloner has investigated the impact of federal and state policies regarding insurance coverage and benefit design related to substance use disorders on access to care and outcomes related to treatment. Dr. Saloner has examined the ability of people in the criminal legal system to access evidence-based substance use disorder treatment. He received an early career award from the National Institute on Drug Abuse to study the effects of Medicaid program design on treatment for opioid use disorder. Another strand of his research focuses broadly on insurance expansions and safety net programs for low-income populations. He has published widely on access to primary care services in relation to the Affordable Care Act Medicaid expansion. He has also published on Medicaid redesign related to premiums and cost-sharing and on public insurance programs for children and adolescents. Finally, Professor Saloner has studied the ethics of resource allocation and normative issues related to health insurance policy.
No Relevant Financial Disclosures
Anika Alvanzo
MD, MS, DFASAM, FACP
Anika Alvanzo, MD, MS, DFASAM, FACP is the Eastern Region Medical Director for Pyramid Healthcare, Inc. She also serves as a physician consultant on substance use disorders to the Behavioral Health Administration in the Maryland Department of Health and is the Managing Partner of Uzima Consulting Group, LLC, which provides addiction medicine-related consultation, education and training, and expert witness testimony. Dr. Alvanzo is a graduate of the George Washington University School of Medicine and Health Sciences and holds a master’s degree in biostatistics from Virginia Commonwealth University. She is board certified in Internal Medicine and Addiction Medicine. Dr. Alvanzo is a Distinguished Fellow of ASAM, a Past President of the Maryland-DC Society of Addiction Medicine (MDDCSAM), and currently serves as Chair of the ASAM Annual Conference Program Planning Committee and Region V Director for the ASAM Board of Directors.
At Pyramid Healthcare, Inc., Dr. Alvanzo’s role is to optimize and standardize the medical care, with emphasis on substance withdrawal management and pharmacotherapy, in the residential and outpatient addiction treatment programs in Eastern Pennsylvania and Maryland. Prior to this, Dr. Alvanzo spent twelve years as faculty in the Divisions of General Internal Medicine and Addiction Medicine at Johns Hopkins University School of Medicine where she held a variety of clinical leadership roles, including Associate Medical Director of Addiction Treatment Services and the Center for Addiction and Pregnancy and Medical Director of the Broadway Center for Addiction, comprehensive, outpatient substance use disorder treatment (SUD) programs on the Johns Hopkin Bayview and Johns Hopkins Hospital campuses, respectively. From 2011 – 2018, Dr. Alvanzo directed the Substance Use Disorders Consultation Service, a multidisciplinary addiction consultation service serving the Johns Hopkins Hospital Department of Medicine general and subspecialty services.
Dr. Alvanzo has served as an expert on National Institutes of Health (NIH), Substance Abuse and Mental Health Services Administration (SAMHSA), National Academies of Sciences, Engineering and Medicine (NASEM), National Quality Forum (NQF) and PEW Research Center panels regarding opioids and integration of recovery-oriented care in various medical settings.
No Relevant Financial Disclosures
Beth McGinty, PhD, MS
Professor
Johns Hopkins Bloomberg School of Public Health
Dr. Beth McGinty is a Professor of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health. At Johns Hopkins, Dr. McGinty serves as Co-Director of the Center for Mental Health and Addiction Policy Research and Co-Director of the ALACRITY Center for Health and Longevity in Mental Illness. Dr. McGinty is a mixed-methods researcher who studies the implementation and outcomes of mental health and substance use policies. She received her MS from Columbia University in 2006 and her PhD from the Johns Hopkins Bloomberg School of Public Health in 2013.
No Relevant Financial Disclosures
CME, CE, CEU and Other Credit Types
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
NAADAC, the Association for Addiction Professionals
This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1222
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1222
Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.
Maintenance of Certification (MOC) / Continuing Certification Program (CCP)
The ASAM State of the Art Course meets the CME requirements for the following primary boards:
• American Board of Medical Specialties (ABMS)
• American Board of Preventive Medicine (ABPM)
• American Board of Anesthesiology (ABA)
• American Board of Pediatrics (ABP)
• American Board of Internal Medicine (ABIM)
• American Board of Surgery (ABS)
• American Board of Psychiatry and Neurology (ABPN)
• American Board of Addiction Medicine (ABAM)
• Royal College of Physicians and Surgeons of Canada (RCPSC
Disclosure Information
In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.